Calcium channel blockers in cardiovascular pharmacotherapy

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 6, 2014, Pages 501-515

  Godfraind, Theophile ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

angina; atherosclerosis; calcium channel blockers; cardiac arrhythmias; heart disease; hypertension; nephropathy

Indexed keywords

4,7 DIHYDRO 3 ISOBUTYL 6 METHYL 4 (3 NITROPHENYL)THIENO[2,3 B]PYRIDINE 5 CARBOXYLIC ACID METHYL ESTER; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CINNARIZINE; CYCLOSPORIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; FELODIPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISRADIPINE; LACIDIPINE; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; NON DIHYDROPYRIDINE; PERINDOPRIL; PINAVERIUM BROMIDE; PROPRANOLOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; ANTIARRHYTHMIC AGENT; VASODILATOR AGENT;

AGING; ANGINA PECTORIS; ANKLE EDEMA; ANTIHYPERTENSIVE THERAPY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CONSTIPATION; CORONARY ARTERY; DEMENTIA; DRUG BINDING SITE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; FOOT EDEMA; GINGIVA HYPERTROPHY; HAND EDEMA; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HEART PALPITATION; HEART STRIUM FLUTTER; HUMAN; HYPERTENSION; KIDNEY DISEASE; MENTAL DETERIORATION; NONHUMAN; OXIDATIVE STRESS; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUBARACHNOID HEMORRHAGE; TABLET FORMULATION; TACHYCARDIA; TREATMENT RESPONSE; VASCULAR SMOOTH MUSCLE; ANIMAL; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VASODILATATION;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS;

EID: 84908887580     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414530508     Document Type: Article

References (115)

1. Schaper WK, Xhoneux R, Jageneau AH, Janssen PA. The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator. J Pharmacol Exp Ther. 1966 ; 152 (2). 265-274
2. Haas H. Zum wirkungsmechanismus des alpha-isoprpyl-alpha-[(N-methyl-N-homoveratridil)-gamma-aminopropyl]-3,4-dimetoxyphenylacetonitrils, einer substanz mit coronargefässerweiternden eigenschaften. Arzneim-Forsch. 1964 ; 12: 461-468
3. Vater W, Kroneberg G, Hoffmeister F, et al. [Pharmacology of 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (Nifedipine, BAY a 1040)]. Arzneimittelforschung. 1972 ; 22 (1). 1-14
4. Sato M, Nagao T, Yamaguchi I, Nakajima H, Kiyomoto A. Pharmacological studies on a new l,5-benzothiazepine derivative (CRD-401). Arzneimittelforschung. 1971 ; 21 (9). 1338-1343
5. Godfraind T, Kaba A, Polster P. Specific antagonism to the direct and indirect action of angiotensin on the isolated guinea-pig ileum. Br J Pharmacol Chemother. 1966 ; 28 (1). 93-104
6. Godfraind T, Kaba A. The role of calcium in the action of drugs on vascular smooth muscle. Arch Int Pharmacodyn Ther. 1972 ; 196 (suppl 196). 35-49
7. Godfraind T, Kaba A. Inhibition by cinnarizine and chlorpromazine of the contraction induced by calcium and adrenaline in vascular smooth muscle. Br J Pharmacol. 1969 ; 35 (2). P354 - P355
8. Godfraind T, Kaba A, Polster P. Differences in sensitivity of arterial smooth muscles to inhibition of their contractile response to depolarization by potassium. Arch Int Pharmacodyn Ther. 1968 ; 172 (1). 235-239
9. Godfraind T, Kaba A. Blockade or reversal of the contraction induced by calcium and adrenaline in depolarized arterial smooth muscle. Br J Pharmacol. 1969 ; 36 (3). 549-560
10. Godfraind T, Polster P. Etude comparative de médicaments inhibant la réponse contractile de vaisseaux isolés d'origine humaine ou animale. Thérapie. 1968 ; 23 (5). 1209-1220
11. Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev. 1986 ; 38 (4). 321-416
12. Fleckenstein A. History of calcium antagonists. Circ Res. 1983 ; 52 (2 pt 2). I3 - I16
13. Godfraind T. Calcium entry blockade and excitation contraction coupling in the cardiovascular system (with an attempt of pharmacological classification). Acta Pharmacol Toxicol (Copenh). 1986 ; 58 (suppl 2). 5-30
14. Godfraind T Calcium Channel Blockers. Basel/ Boston/Berlin: Birkhaäuser Verlag ; 2004 :
15. Evans DHL, Schild HO, Thesleff S. Effect of drugs on depolarized plain muscle. J Physiol. 1958 ; 143 (3). 474-485
16. Edman KAP, Schild HO. Interaction of acetylcholine, calcium and depolarization in the contraction of smooth muscle. Nature. 1961 ; 190: 350-352
17. Edman KAP, Schild HO. Calcium and the stimulant and inhibitory effects of adrenaline in depolarized smooth muscle. J Physiol. 1963 ; 169: 404-411
18. Edman KAP, Schild HO. The need for calcium in the contractile responses induced by acetylcholine and potassium in the rat uterus. J Physiol. 1962 ; 161: 424-441
19. Wibo M, DeRoth L, Godfraind T. Pharmacologic relevance of dihydropyridine binding sites in membranes from rat aorta: kinetic and equilibrium studies. Circ Res. 1988 ; 62 (1). 91-96
20. Godfraind T, Wibo M. Subcellular localization of [3H]-nitrendipine binding sites in guinea-pig ileal smooth muscle. Br J Pharmacol. 1985 ; 85 (2). 335-340
21. Grover AK, Kwan CY, Luchowski E, Daniel EE, Triggle DJ. Subcellular distribution of [3H]nitrendipine binding in smooth muscle. J Biol Chem. 1984 ; 259 (4). 2223-2226
22. Triggle DJ. The pharmacology of ion channels: with particular reference to voltage-gated Ca2+ channels. Eur J Pharmacol. 1999 ; 375 (1-3). 311-325
23. Triggle DJ. Calcium channel antagonists: clinical uses-past, present and future. Biochem Pharmacol. 2007 ; 74 (1). 1-9
24. Nowycky MC, Fox AP, Tsien RW. Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature. 1985 ; 316 (6027). 440-443
25. Ertel EA, Campbell KP, Harpold MM, et al. Nomenclature of voltage-gated calcium channels. Neuron. 2000 ; 25 (3). 533-535
26. Perez-Reyes E, Van Deusen AL, Vitko I. Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 ; 328 (2). 621-627
27. Godfraind T. Calcium antagonists and vasodilatation. Pharmacol Ther. 1994 ; 64 (1). 37-75
28. Godfraind T, Morel N, Wibo M. Tissue specificity of dihydropyridine-type calcium antagonists in human isolated tissues. Trends Pharmacol Sci. 1988 ; 9 (1). 37-39
29. Godfraind T, Finet M, Lima JS, Miller RC. Contractile activity of human coronary arteries and human myocardium in vitro and their sensitivity to calcium entry blockade by nifedipine. J Pharmacol Exp Ther. 1984 ; 230 (2). 514-518
30. Sun J, Triggle DJ. Calcium channel antagonists: cardiovascular selectivity of action. J Pharmacol Exp Ther. 1995 ; 274 (1). 419-426
31. Godfraind T, Salomone S, Dessy C, Verhelst B, Dion R, Schoevaerts JC. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J Cardiovasc Pharmacol. 1992 ; 20 (suppl 5). S34 - S41
32. Opie LH, Yusuf S, Kubler W. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Prog Cardiovasc Dis. 2000 ; 43 (2). 171-196
33. Leonetti G, Cuspidi C, Sampieri L, Terzoli L, Zanchetti A. Comparison of cardiovascular, renal, and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects. J Cardiovasc Pharmacol. 1982 ; 4 (suppl 3). S319 - S324
34. Godfraind T. Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond B Biol Sci. 2005 ; 360 (1464). 2259-2272
35. Napoli C, Salomone S, Godfraind T, et al. 1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats. Stroke. 1999 ; 30 (9). 1907-1915
36. Kyselovic J, Martinka P, Batova Z, Gazova A, Godfraind T. Calcium channel blocker inhibits western-type diet-evoked atherosclerosis development in ApoE-deficient mice. J Pharmacol Exp Ther. 2005 ; 315 (1). 320-328
37. Krenek P, Salomone S, Kyselovic J, Wibo M, Morel N, Godfraind T. Lacidipine prevents endothelial dysfunction in salt-loaded stroke-prone hypertensive rats. Hypertension. 2001 ; 37 (4). 1124-1128
38. Massart PE, Donckier J, Kyselovic J, Godfraind T, Heyndrickx GR, Wibo M. Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding. Hypertension. 1999 ; 34 (6). 1197-1201
39. Godfraind T, Mennig D, Bravo G, Chalant C, Jaumin P. Inhibition by amlodipine of activity evoked in isolated human coronary arteries by endothelin, prostaglandin F2 alpha and depolarization. Am J Cardiol. 1989 ; 64 (17). 58I - 64I
40. Feron O, Salomone S, Godfraind T. Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats. Br J Pharmacol. 1996 ; 118 (3). 659-664
41. Feron O, Salomone S, Godfraind T. Blood pressure-independent inhibition by lacidipine of endothelin-1-related cardiac hypertrophy in salt-loaded, stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1995 ; 26 (suppl 3). S459 - S461
42. Krippeit-Drews P, Morel N, Godfraind T. Effect of nitric oxide on membrane potential and contraction of rat aorta. J Cardiovasc Pharmacol. 1992 ; 20 (suppl 12). S72 - S75
43. Batova S, DeWever J, Godfraind T, Balligand JL, Dessy C, Feron O. The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Cardiovasc Res. 2006 ; 71 (3). 478-485
44. Salomone S, Silva CL, Morel N, Godfraind T. Facilitation of the vasorelaxant action of calcium antagonists by basal nitric oxide in depolarized artery. Naunyn Schmiedebergs Arch Pharmacol. 1996 ; 354 (4). 505-512
45. Godfraind T, Salomone S. Calcium antagonists and endothelial function: focus on nitric oxide and endothelin. Cardiovasc Drugs Ther. 1996 ; 10 (4). 439-446
46. Kyselovic J, Krenek P, Wibo M, Godfraind T. Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats. Br J Pharmacol. 2001 ; 134 (7). 1516-1522
47. Balligand JL, Godfraind T. Amlodipine and stroke prevention. Hypertension. 2007 ; 50 (4). e71
48. Furberg CD, Psaty BM, Meyer JV. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995 ; 92 (5). 1326-1331
49. Opie LH, Schall R. Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J Am Coll Cardiol. 2002 ; 39 (2). 315-322
50. Opie LH, Messerli FH. Grave defects in the dossier. Circulation. 1995 ; 92 (5). 1068-1073
51. JAMA. 2002: 2981-2997.
52. Chrysant SG. The ALLHAT study: results and clinical implications. QJM. 2003 ; 96 (10). 771-773
53. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002 ; 288 (23). 2981-2997
54. Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006 ; 48 (3). 374-384
55. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004 ; 364 (9437). 849-857
56. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014 ; 311 (5). 507-520
57. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003 ; 42 (6). 1206-1252
58. Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American heart association, the American college of cardiology, and the centers for disease control and prevention. Hypertension. 2014 ; 63 (12). 1230-1238
59. McDonagh MS, Eden KB, Peterson K Drug Class Reviews. Mar 2005:
60. Ryuzaki M, Nakamoto H, Nishida E, et al. Crossover study of amlodipine versus nifedipine CR with home blood pressure monitoring via cellular phone: internet-mediated open-label crossover trial of calcium channel blockers for hypertension (i-TECHO trial). J Hypertens. 2007 ; 25 (11). 2352-2358
61. Godfraind T, Egleme C, Finet M, Jaumin P. The actions of nifedipine and nisoldipine on the contractile activity of human coronary arteries and human cardiac tissue in vitro. Pharmacol Toxicol. 1987 ; 61 (2). 79-84
62. Pfisterer ME, Zellweger MJ, Gersh BJ. Management of stable coronary artery disease. Lancet. 2010 ; 375 (9716). 763-772
63. Opie LH. First line drugs in chronic stable effort angina - the case for newer, longer-acting calcium channel blocking agents. J Am Coll Cardiol. 2000 ; 36 (6). 1967-1971
64. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American college of cardiology foundation/American heart association task force on practice guidelines, and the American college of physicians, American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. Circulation. 2012 ; 126 (25). e354 - e471
65. Frishman WH.. beta-Adrenergic blockade in cardiovascular disease. J Cardiovasc Pharmacol Ther. 2013 ; 18 (4). 310-319
66. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 ; 366 (9489). 895-906
67. Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002 ; 106 (19). 2422-2427
68. Schamroth L. Immediate effects of intravenous verapamil on atrial fibrillation. Cardiovasc Res. 1971 ; 5 (4). 419-424
69. Singh BN. A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res. 1972 ; 6 (2). 109-119
70. Nademanee K, Singh BN. Control of cardiac arrhythmias by calcium antagonism. Ann N Y Acad Sci. 1988 ; 522: 536-552
71. Schamroth L, Antman E Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. Stone PH man EM, ed. Mount Cisco, New York: Futura Publishing Company, Inc ; 1983 :
72. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC). Eur Heart J. 2010 ; 31 (19). 2369-2429
73. De Simone A, De Pasquale M, De Matteis C, et al. VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). Eur Heart J. 2003 ; 24 (15). 1425-1429
74. Bühler F, Bolli W, Müller F, Erne P Cardiovascular Effects of Dihydropyridine-Type Calcium Antagonists and Agonists. Fleckenstein A Van Breemen C Gross R Hoffmeister F, ed. Berlin, Heidelberg, New york: Springer ; 1985: 445-457.
75. Morel N, Godfraind T. Selective interaction of the calcium antagonist amlodipine with calcium channels in arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1994 ; 24 (4). 524-533
76. Zanchetti A, Stella A. The role of the kidney in neurohormonal cardiovascular regulation. Acta Physiol Scand Suppl. 1988 ; 571: 69-81
77. Zanchetti A. The renin-angiotensin system and the heart. Am J Med. 1988 ; 84 (3A). 1-2
78. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation. 2001 ; 104 (11). 1248-1254
79. Godfraind T. Calcium-channel modulators for cardiovascular disease. Expert Opin Emerg Drugs. 2006 ; 11 (1). 49-73
80. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 ; 361 (9364). 1149-1158
81. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by Amlodipine and Angiotensin receptor blockers. A quantitative overview. Hypertension. 2007 ; 50 (1). 181-188
82. Sasaki H, Saiki A, Endo K, et al. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. J Atheroscler Thromb. 2009 ; 16 (5). 568-575
83. Ozawa Y, Hayashi K, Nagahama T, Fujiwara K, Wakino S, Saruta T. Renal afferent and efferent arteriolar dilation by nilvadipine: studies in the isolated perfused hydronephrotic kidney. J Cardiovasc Pharmacol. 1999 ; 33 (2). 243-247
84. Hayashi K, Kumagai H, Saruta T. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens. 2003 ; 16 (2). 116-122
85. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW.. INTACT group investigators. Lancet. 1990 ; 335 (8698). 1109-1113
86. Zanchetti A, Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A. The verapamil in hypertension and atherosclerosis study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens. 1998 ; 16 (11). 1667-1676
87. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000 ; 102 (13). 1503-1510
88. Simon A, Gariepy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation. 2001 ; 103 (24). 2949-2954
89. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). A randomized controlled trial. JAMA. 1996 ; 276 (10). 785-791
90. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007 ; 120 (8). 713-719
91. Chrysant SG, Lee J, Melino M, Karki S, Heyrman R. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens. 2010 ; 24 (11). 730-738
92. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008 ; 30 (4). 587-604
93. Oparil S, Chrysant SG, Melino M, Lee J, Karki S, Heyrman R. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil +/- hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial. J Hum Hypertens. 2010 ; 24 (12). 831-838
94. Fogari R, Malamani G, Corradi L, et al. Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. Adv Ther. 2010 ; 27 (1). 48-55
95. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009 ; 54 (1). 32-39
96. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010 ; 32 (7). 1252-1269
97. Fogari R, Mugellini A, Preti P, Zoppi A, Derosa G. Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine. Vasc Health Risk Manag. 2010 ; 6: 87-93
98. Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther. 2001 ; 23 (8). 1166-1179
99. Stanton T, Reid JL. Fixed dose combination therapy in the treatment of hypertension. J Hum Hypertens. 2002 ; 16 (2). 75-78
100. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 ; 359 (23). 2417-2428
101. Afanas'ev Iu I, Storozhenko S, Grigorova S. [Potentialities of medicinal correction of cerebrovascular disturbances in patients with arterial hypertension]. Klin Med (Mosk). 2012 ; 90 (6). 66-69
102. Efimova I, Kalashnikova TP. Lishmanov Iu B. [The impact of antihypertensive therapy on cerebral hemodynamics in patients with metabolic syndrome]. Klin Med (Mosk). 2012 ; 90 (8). 36-41
103. Chalmers J, Arima H, Woodward M, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014 ; 63 (2). 259-264
104. Kim-Mitsuyama S, Ogawa H, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. Kidney Int. 2013 ; 83 (1). 167-176
105. Godfraind T Calcium channel blockers. Basel, Boston: Birkhäuser Verlag ; 2004 :
106. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009 ; 122 (3). 290-300
107. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003 ; 326 (7404). 1427
108. Bautista LE. Blood pressure-lowering effects of statins: who benefits?. J Hypertens. 2009 ; 27 (7). 1478-1484
109. Martin-Ventura JL, Munoz-Garcia B, Blanco-Colio LM, et al. Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int Suppl. 2008 ; (111). S71 - S74
110. Neutel JM, Bestermann WH, Dyess EM, et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich). 2009 ; 11 (1). 22-30
111. Elliott HL, Meredith PA. Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the 'ACTION' database in patients with angina. J Hum Hypertens. 2011 ; 25 (1). 63-70
112. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011 ; 42 (9). 2672-2713
113. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet. 1997 ; 350 (9080). 757-764
114. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002 ; 162 (18). 2046-2052
115. Nimmrich V, Eckert A. Calcium channel blockers and dementia. Br J Pharmacol. 2013 ; 169 (6). 1203-1210